SCHEMBL3757378

SCHEMBL3757378

Cc1cc(N)ccc1N1CCCN(CCO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)C1=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMYD2 Q9NRG4 3/20 0.37
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
THRB P10828 1/20 0.37
NR4A1 P22736 1/20 0.37
PTK2B Q14289 1/20 0.37
PER2 O15055 1/20 0.35
RAD52 P43351 1/20 0.34
GFER P55789 1/20 0.34
MAPK1 P28482 1/20 0.32
SCN9A Q15858 1/20 0.31
TAS2R8 Q9NYW2 1/20 0.30
CYP3A4 P08684 1/20 0.30
HTT P42858 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3745187 0.90 MAPT (0.37) SMYD2GAAMAPTALDH1A1PER2
SCHEMBL3760372 0.88 SMYD2 (0.36) SMYD2MAPTPER2SCN9ACYP3A4
SCHEMBL3752623 0.87 SMYD2 (0.35) SMYD2GAAMAPTKMT2AMEN1
SCHEMBL5482915 0.85 PER2 (0.39) SMYD2PER2TAS2R8CYP3A4HTT
SCHEMBL3645438 0.79 ALDH1A1 (0.41) SMYD2GAAMAPTKMT2AMEN1
SCHEMBL2993811 0.79 PER2 (0.40) SMYD2PER2SCN9A
SCHEMBL3748433 0.78 HTR7 (0.37) SMYD2MAPTKMT2AMEN1ALDH1A1
SCHEMBL5482922 0.76 SMYD2 (0.38) SMYD2GAAMAPTKMT2AMEN1
SCHEMBL16502678 0.75 MAPT (0.47) GAAMAPTKMT2AMEN1ALDH1A1
SCHEMBL29051774 0.73 SMYD2 (0.38) SMYD2GAAMAPTALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-8198267-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
EP-2167499-B1 SUBSTITUTED OXAZOLIDINONES AND USE THEREOF Bayer Pharma AG (DE) 2011-12-14 EP disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA ATIENGESELLSCHAFT (DE) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298293-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, OXA1L, PPOX SMYD2 4432/4885GAA 833/4885MAPT 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.